文献速递主动脉疾病

多中心研究:远端多孔Talos覆膜支架置入后无并发症B型主动脉夹层患者的中期结局

A Multicenter Study of the Mid-term Outcomes of Patients with Uncomplicated Type B Aortic Dissection After Distal Porous Talos Stent-Graft Implantation.
PubMed 文献 · Ann Vasc Surg · 2024-04-09

该多中心回顾性研究分析了113例无并发症B型主动脉夹层患者接受远端多孔Talos覆膜支架置入后的中期结局。30天死亡率为0.9%(1/113),12个月治疗成功率为99.1%(112/113),随访中位34个月时3年生存率为91.7%。作者认为Talos覆膜支架在安全性和有效性方面结果满意,但需更多数据确认长期性能。

要点

  • 30天死亡率为0.9%(1/113),无中转开放手术或器械相关不良事件。
  • 12个月治疗成功率为99.1%(112/113),无夹层相关再干预。
  • 中位随访34个月,3年生存率为91.7%,支架段假腔完全血栓化率为80.5%(91/113)。

核心结论

  • 作者认为Talos覆膜支架在无并发症B型主动脉夹层患者中安全性和有效性结果满意,但需更多数据确认长期性能。

研究设计与样本

  • 多中心回顾性研究,纳入113例无并发症B型主动脉夹层患者,平均年龄54.4(11.1)岁,男性占71.7%(81/113)。
  • 主要安全终点为30天主要不良事件,包括全因死亡、夹层相关死亡、中转开放手术和器械相关不良事件;主要有效性终点为术后12个月治疗成功,定义为无技术失败或夹层相关二次再干预。
  • 采用Kaplan-Meier曲线显示患者生存状态,在4个水平评估主动脉增长,并在12个月评估脊髓缺血。

主要发现

  • 30天死亡率为0.9%(1/113),无中转开放手术和器械相关不良事件记录。
  • 12个月治疗成功率为99.1%(112/113),无夹层相关再干预;12个月无脊髓缺血或内脏缺血。
  • 中位随访34个月期间记录到9例额外死亡,3年生存率为91.7%。
  • 主动脉增长百分比分别为:气管分叉处1.8%(2/111)、左心房下方3.6%(4/111)、腹腔干上方6.0%(5/83)、下肾动脉下方12.1%(9/74)。
  • 支架段假腔总血栓化率为80.5%(91/113)。

局限性

  • 原文结论指出需更多数据确认长期性能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Talos stent-graft has extended length to improve aortic remodeling, and distal porous design to decrease the rate of spinal cord ischemia (SCI). This study retrospectively analyzed its mid-term outcomes for uncomplicated type B aortic dissection in a multicenter study. METHODS: The primary safety end point was 30-day major adverse events, including all-cause mortality, dissection-related mortality, conversion to open surgery, and device-related adverse events. The primary efficacy end point was treatment success at 12 months postoperation, defined as no technical failure or secondary dissection-related reintervention. The survival status of the patients was visualized using the Kaplan-Meier curve. Aortic growth was assessed at 4 levels, and SCI was evaluated at 12 months. RESULTS: 113 patients participated with a mean age of 54.4 (11.1) years and 71.7% (81/113) were male. The 30-day mortality was 0.9% (1/113), no conversions to open surgery or device-related adverse events were recorded. The 12-month treatment success rate was 99.1% (112/113), with no dissection-related reinterventions. There was no spinal cord or visceral ischemia at 12 months. At a median of 34 months follow-up, 9 further deaths were recorded and the 3-year survival rate was 91.7%. The percentage of aortic growth was 1.8% (2/111) at the tracheal bifurcation, 3.6% (4/111) below the left atrium, 6.0% (5/83) above the celiac artery, and 12.1% (9/74) below the lower renal artery. The total thrombosis rate of the false lumen at the stented segment was 80.5% (91/113). CONCLUSIONS: The results showed satisfactory results of Talos stent-graft in terms of safety and efficacy. More data are needed to confirm the long-term performance.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Shu C, Fang K, Chen D, et al. A Multicenter Study of the Mid-term Outcomes of Patients with Uncomplicated Type B Aortic Dissection After Distal Porous Talos Stent-Graft Implantation. Ann Vasc Surg. 2024. PMID: 38599492. doi:10.1016/j.avsg.2024.02.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。